530 related articles for article (PubMed ID: 29689073)
21. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
22. Current and future HCV therapy: do we still need other anti-HCV drugs?
Petta S; Craxì A
Liver Int; 2015 Jan; 35 Suppl 1():4-10. PubMed ID: 25529081
[TBL] [Abstract][Full Text] [Related]
23. Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.
Poovorawan K; Pan-Ngum W; White LJ; Soonthornworasiri N; Wilairatana P; Wasitthankasem R; Tangkijvanich P; Poovorawan Y
PLoS One; 2016; 11(9):e0163095. PubMed ID: 27631382
[TBL] [Abstract][Full Text] [Related]
24. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
25. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
[TBL] [Abstract][Full Text] [Related]
26. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.
Litzroth A; Suin V; Wyndham-Thomas C; Quoilin S; Muyldermans G; Vanwolleghem T; Kabamba-Mukadi B; Verburgh V; Jacques M; Van Gucht S; Hutse V
BMC Public Health; 2019 Jan; 19(1):39. PubMed ID: 30621662
[TBL] [Abstract][Full Text] [Related]
27. Uptake of and Expenditure on Direct-Acting Antiviral Agents for Hepatitis C Treatment in Australia.
de Graaff B; Yee KC; Clarke P; Palmer A
Appl Health Econ Health Policy; 2018 Aug; 16(4):495-502. PubMed ID: 29675692
[TBL] [Abstract][Full Text] [Related]
28. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
[TBL] [Abstract][Full Text] [Related]
29. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
[TBL] [Abstract][Full Text] [Related]
31. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
[TBL] [Abstract][Full Text] [Related]
32. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis C virus: A time for decisions. Who should be treated and when?
Attar BM; Van Thiel DH
World J Gastrointest Pharmacol Ther; 2016 Feb; 7(1):33-40. PubMed ID: 26855810
[TBL] [Abstract][Full Text] [Related]
34. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
Kondili LA; Blach S; Razavi H; Craxì A
Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination.
Wasitthankasem R; Pimsingh N; Treesun K; Posuwan N; Vichaiwattana P; Auphimai C; Thongpan I; Tongsima S; Vongpunsawad S; Poovorawan Y
Am J Trop Med Hyg; 2020 Jul; 103(1):175-182. PubMed ID: 32394881
[TBL] [Abstract][Full Text] [Related]
36. Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
Müllhaupt B; Bruggmann P; Bihl F; Blach S; Lavanchy D; Razavi H; Robbins Scott S; Semela D; Negro F
PLoS One; 2018; 13(12):e0209374. PubMed ID: 30596701
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation.
Zhong H; Aaron A; Hiebert L; Serumondo J; Zhuo Y; Adee M; Rwibasira GN; Ward JW; Chhatwal J
Value Health; 2024 Jul; 27(7):918-925. PubMed ID: 38492923
[TBL] [Abstract][Full Text] [Related]
38. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
Dore GJ; Hajarizadeh B
Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals.
Chhatwal J; Wang X; Ayer T; Kabiri M; Chung RT; Hur C; Donohue JM; Roberts MS; Kanwal F
Hepatology; 2016 Nov; 64(5):1442-1450. PubMed ID: 27015107
[TBL] [Abstract][Full Text] [Related]
40. "Waiting for DAAs": A retrospective chart review of patients with untreated hepatitis C in Rwanda.
Gupta N; Kabahizi J; Mukabatsinda C; Walker TD; Musabeyezu E; Kiromera A; Van Nuil JI; Steiner K; Mukherjee J; Nsanzimana S; Mbituyumuremyi A
PLoS One; 2017; 12(3):e0174148. PubMed ID: 28323868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
